Shots:
- Tracer has entered into a strategic collaboration with QIAGEN to co-develop & commercialize Tracer dPCR & Tracer WGS MRD assays for solid tumors on QIAGEN’s QIAcuity digital PCR platform
- Collaboration aims to provide highly sensitive, cost-effective, & decentralized MRD testing using QIAcuity’s PCR platform, allowing oncologists to monitor cancer recurrence & guide personalized treatment decisions with seamless integration into clinical workflows
- Tracer dPCR is a tumor-informed, multiplexed digital PCR assay allowing institutions to run bespoke MRD tests on their own instruments, while Tracer WGS is an AI-driven whole-genome ctDNA platform for ultra-sensitive, tumor-agnostic detection without prior tissue sample
Ref: Businesswire | Image: Tracer Biotechnologies & Qiagen| Press Release
Related News:- QIAGEN to Acquire Genoox for ~$80M
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
